Outcome measures for clinical trials in interstitial lung diseases

Current Respiratory Medicine Reviews

Volumn 11, Issue 2, 2015, Pages 163-174

  Lammi, Matthew R ^a,b   Baughman, Robert P ^c   Birring, Surinder S ^d   Russell, Anne Marie ^e   Ryu, Jay H ^f   Scholand, Mary Beth ^g   Distler, Oliver ^h   Lesage, Daphne ⁱ   Sarver, Catherine ^j   Antoniou, Katerina ^k   Highland, Kristin B ^l   Kowal Bielecka, Otylia ^m   Lasky, Joseph A ^b,n   Wells, Athol U ^e   Saketkoo, Lesley Ann ^b,n  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f Mayo Clinic College of Medicine   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ Patient Research Partner Office of Public Health   (United States)

^j Patient Research Partner   (United States)

^k UNIVERSITY OF CRETE   (Greece)

^l LERNER RESEARCH INSTITUTE   (United States)

^m MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

ⁿ TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Chronic fibrosing; Connective tissue disease related interstitial lung disease; Idiopathic interstitial pneumonia; Idiopathic pulmonary fibrosis; Rheumatoid arthritis; Scleroderma; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE;

ARTICLE; CLINICAL RESEARCH; CONNECTIVE TISSUE DISEASE; COUGHING; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; EXERCISE TEST; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG DIFFUSION CAPACITY; OUTCOME ASSESSMENT; OXYGEN DESATURATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC SCLEROSIS; VISUAL ANALOG SCALE;

EID: 84942102997     PISSN: 1573398X     EISSN: 18756387     Source Type: Journal    
DOI: 10.2174/1573398X11666150619183527     Document Type: Article

References (128)

1. Travis WD, Costabel U, Hansell DM, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med 2013; 188(6): 733-48.
2. Moore CF Jr, Perez RL. Comparison of Idiopathic Interstitial Pneumonias with Their Connective Tissue Disease-Associated Counterparts. Curr Resp Med Rev 2015; 11(2): in press.
3. Jokerst C, Azok J, Cummings KW, Bhalla S. High-Resolution CT Imaging Findings of Collagen Vascular Disease-Associated Interstitial Lung Disease. Curr Resp Med Rev 2015; 11(2): in press.
4. American Thoracic Society/European Respiratory Society Statement on Interstitial Pulmonary Autoimmune Fibrosis. American Thoracic Society/European Respiratory Society Task Force-"An International Working Group on Undifferentiated Forms of CTD-ILD". Aryeh Fischer, Chair. In press.
5. Solomon JJ, Ryu JH, Tazelaar HD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritisassociated interstitial lung disease (RA-ILD). Respir Med 2013; 107(8): 1247-52.
6. Song JW, Lee HK, Lee CK. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30(2): 103-12.
7. Buch MH, Denton CP, Furst DE, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 2007; 66(2): 169-73.
8. Wilsher M, Good N, Hopkins R, et al. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology 2012; 17(4): 647-52.
9. Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63(9): 2797-808.
10. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25): 2655-66.
11. Hinchcliff M, Beaumont JL, Thavarajah K, et al. Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken) 2011; 63(11): 1620-8.
12. Saketkoo LA, Mittoo S, Huscher D, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014; 69(5): 428-36.
13. Saketkoo LA, Mittoo SM, Frankel S, et al. Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease Related Interstitial Lung Diseases. J Rheumatol. 2014; 41(4): 792-8.
14. King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370(22): 2083-92.
15. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370(22): 2071-82.
16. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-81.
17. Medical Research Council. Committee on research on chronic bronchitis. Instructions for use of the questionnaire on respiratory symptoms. Devon, UK: W.J. Holdman 1966.
18. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of selfadministered versions of modified baseline and transition dyspnea indexes in COPD. COPD 2004; 1(2): 165-72.
19. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998; 113(3): 619-24.
20. Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax 2010; 65(1): 21-6.
21. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1): 111-7.
22. Wilson RC, Jones PW. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond) 1989; 76(3): 277-82.
23. Wilson RC, Jones PW. Long-term reproducibility of Borg scale estimates of breathlessness during exercise. Clin Sci (Lond) 1991; 80(4): 309-12.
24. Papiris SA, Daniil ZD, Malagari K, et al. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005; 99(6): 755-61.
25. Manali ED, Lyberopoulos P, Triantafillidou C, et al. MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med 2010; 10: 32. doi: 10.1186/1471-2466-10-32.:32-10.
26. Yorke J, Swigris J, Russell AM, et al. Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest 2011; 139(1): 159-64.
27. Holland AE, Fiore JF Jr, Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014; 19(8): 1215-21.
28. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85(6): 751-8.
29. Khanna D, Tseng CH, Furst DE, et al. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. Rheumatology (Oxford) 2009; 48(12): 1537-40.
30. Swigris JJ, Yorke J, Sprunger DB, et al. Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med 2010; 104(9): 1350-5.
31. Swigris JJ, Han M, Vij R, et al. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med. 2012; 106(10): 1447-55.
32. Raj AA, Birring SS. Clinical assessment of chronic cough severity. Pulm Pharmacol Ther 2007; 20(4): 334-7.
33. Brignall K, Jayaraman B, Birring SS. Quality of life and psychosocial aspects of cough. Lung 2008; 186 Suppl 1: S55-S58.
34. Raj AA, Pavord ID, Birring SS. What is the minimal important difference of the Leicester Cough Questionnaire? In: Chung KF, Widdicombe J, Eds. Pharmacology and Therapeutics of Cough. Berlin: Springer 2009; 311-20.
35. Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16(6): 969-75.
36. Theodore AC, Tseng CH, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest 2012; 142(3): 614-21.
37. Birring SS, Parker D, McKenna S, et al. Sputum eosinophilia in idiopathic pulmonary fibrosis. Inflamm Res 2005; 54(2): 51-6.
38. Birring SS. Developing antitussives: the ideal clinical trial. Pulm Pharmacol Ther 2009; 22(2): 155-8.
39. Birring SS, Parker D, Brightling CE, et al. Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med 2004; 169(1): 15-9.
40. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58(4): 339-43.
41. French CT, Irwin RS, Fletcher KE, Adams TM. Evaluation of a cough-specific quality-of-life questionnaire. Chest 2002; 121(4): 1123-31.
42. Davenport PW. Clinical cough I: the urge-to-cough: a respiratory sensation. Handb Exp Pharmacol 2009; 187: 263-76.
43. Birring SS, Matos S, Patel RB, Prudon B, Evans DH, Pavord ID. Cough frequency, cough sensitivity and health status in patients with chronic cough. Respir Med 2006; 100(6): 1105-9.
44. Birring SS, Fleming T, Matos S, Raj AA, Evans DH, Pavord ID. The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 2008; 31(5): 1013-8.
45. Barton A, Gaydecki P, Holt K, Smith JA. Data reduction for cough studies using distribution of audio frequency content. Cough 2012; 8(1): 12.
46. Prudon B, Birring SS, Vara DD, Hall AP, Thompson JP, Pavord ID. Cough and glottic-stop reflex sensitivity in health and disease. Chest 2005; 127(2): 550-7.
47. Huisman AN, Wu MZ, Uil SM, van den Berg JW. Reliability and validity of a Dutch version of the Leicester Cough Questionnaire. Cough 2007; 3: 3.
48. Key AL, Holt K, Hamilton A, Smith JA, Earis JE. Objective cough frequency in Idiopathic Pulmonary Fibrosis. Cough 2010; 6: 4.
49. Lechtzin N, Hilliard ME, Horton MR. Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. Chest 2013; 143(6): 1745-9.
50. Fletcher KE, French CT, Irwin RS, Corapi KM, Norman GR. A prospective global measure, the Punum Ladder, provides more valid assessments of quality of life than a retrospective transition measure. J Clin Epidemiol 2010; 63(10): 1123-31.
51. Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157(6): 398-406.
52. Swigris JJ, Fairclough D. Patient-Reported Outcomes in Idiopathic Pulmonary Fibrosis Res Chest 2012; 142 (2): 291-297.
53. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Qualification Process for Drug Development Tools Silver Spring, MD: US Department of Health and Human Services; 2010.
54. Aaronson N, Choucair A, Elliot T Greenhalgh J, et al. User's guide to Implementing Patient Reported Outcome Measures Assessment in clinical Practice International society for Quality of Life Research Nov 2011
55. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 March 2011
56. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010; 104: 296-304.
57. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): Conceptual framework and item selection. Medical Care 1992; 30: 473-83.
58. Russell AM, Fraser U Molyneaux P, et al. Quality of life measures in patients with idiopathic pulmonary fibrosis. Eur Resp J 2013; 42 Suppl 57: P3368.
59. Swigris J, Gould MK, Wilson SR. Health-Related Quality of Life Among Patients With Idiopathic Pulmonary Fibrosis Chest 2005; 127: 284 -294.
60. Patel AS, Brignall K, Gordon P, Steer S, Wells AU, Higginson I, Birring S. Assessment Of Health Related Quality Of Life (HRQOL) In Connective Tissue Disease Associated Interstitial Lung Diseases (CTD-ILD) Am J Respir Crit Care Med 2011; 183: A3030
61. Yorke J, Jones PW, Swigris JJ, Development and Validity Testing of an IPF-Specific Version of the SGRQ Thorax 2010; 65: 921e926.
62. Martinez J, Martinez T, Galhardo F, et al. Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. Med Sci Monit 2002; 8: CR405-CR410.
63. Chang J, Curtis R, Patrick D, et al. Assessment of Health Related quality of life in patients with interstitial lung disease. Chest 1999; 116: 1175-82.
64. Swigris J, Wilson S, Green K, Spunger D, Brown K, Wambolt F. Development of the ATAQ-IPF: a tool to assess quality of life in IPF Health and Quality of Life Outcomes 2010; 8: 77.
65. Yorke J, Spencer LG, Duck A, et al. Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA) BMJ Open Resp Res 2014; 1: 24.
66. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire Thorax 2012; 67: 804-10.
67. Steen VD, Medsger TA. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 1984-91.
68. Akira M, Kozuka T, Inoue Y, Sakatani M. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest 2005; 127: 185-191.
69. Best AC, Meng J, Lynch AM, et al. Idiopathic Pulmonary Fibrosis: Physiologic Tests, Quantitative CT Indexes, and CT Visual Scores as Predictors of Mortality. Radiology 2008; 246: 935-940.
70. Edey AJ, Devaraj AA, Barker RP, Nicholson AG, Wells AU, Hansell DM. Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol 2011; 21: 1586-1593.
71. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177(11): 1248-54.
72. Goldin J G. Quantitative CT of the lung. Radiol Clin North Am 2002; 40(1): 145-162.
73. Kauczor, H.-U., C. P. Heussel, Herth FJ. Longitudinal quantitative low-dose CT in COPD: ready for use? Lancet Respir Med 2013; 1(2): 95-96.
74. Kazantzi, A., Costaridou L, Skiadopoulos S, et al. Automated 3D Interstitial Lung Disease Extent Quantification: Performance Evaluation and Correlation to PFTs. J Digit Imaging 2014; 27(3): 380-391.
75. Kim HJ, Brown MS, Elashoff R, et al. Quantitative texture-based assessment of one year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 2011; 21: 2455-2465.
76. Kim MY, Song JW, Do KH, Jang SJ, Colby TV, Kim DS. Idiopathic nonspecific interstitial pneumonia: changes in highresolution computed tomography on long-term follow-up. J Comput Assist Tomogr. 2012; 36(2): 170-174.
77. Lee HY, Lee KS, Jeong YJ, et al. High-resolution CT findings in fibrotic idiopathic interstitial pneumonias with little honeycombing: serial changes and prognostic implications. AJR Am J Roentgenol 2012; 199(5): 982-989.
78. Lynch DA, David GJ, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172: 488-493.
79. Maldonado F, Moua T, Rajagopalan S, et al. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 204-212.
80. Nishino M, Itoh H, Hatabu H. A practical approach to highresolution CT of diffuse lung disease. Eur J Radiol 2014; 83(1): 6-19.
81. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
82. Raghunath S, Rajagopalan S, Karwoski RA, et al. Quantitative stratification of diffuse parenchymal lung diseases. PLoS One 2014 ; 9(3): e93229.
83. Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. Mayo Clinic Proceedings 2007; 82(8): 976-986.
84. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings inpathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008; 177: 433-439.
85. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-748.
86. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013; 143(3): 814-824.
87. Walsh SL, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014; 69: 216-222.
88. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969.
89. Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013; 266: 936-944.
90. Silva CI, Muller NL, Hansell DM, Lee KS, Nicholson AG, Wells AU. Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology 2008; 247: 251-259.
91. Du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
92. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012; 40: 101-109.
93. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: The ILD-GAP model. Chest 2013; 145: 723-728.
94. Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164: 103-108.
95. Jeong YJ, Lee KS, Muller NL, et al. Usual interstitial pneumonia and non-specific interstitial pneumonia: serial thin-section CT findings correlated with pulmonary function. Korean J Radiol 2005; 6: 143-152.
96. Iwasawa T, Ogura T, Sakai F, et al. CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. Eur J Radiol 2014; 83: 32-38.
97. Kim EA, Johkoh T, Lee KS, et al. Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation. J Comput Assist Tomogr 2001; 25: 757-763.
98. Winklehner A, Berger N, Maurer B, Distler O, Alkadhi H, Frauenfelder T. Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis 2012; 71: 549-552.
99. Wells AU, Behr J, Silver R. Outcome measures in the lung. Rheumatology 2008; 47: v48-v50.
100. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161(2 Pt 1): 646-64.
101. Bradford WZ, Cohen AH, Leff JA. Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 2013; 187(11): 1269-1270.
102. King JR TE, Safrin S, Starko KM, Brown KK, Nobel PW, Raghu G, et al. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-177.
103. duBois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Resp Crit Care Med 2011; 184: 1382-1389.
104. Steen VD, Conte C, Owens GR, Medsger Jr TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-1289.
105. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Resp Crit Care Med 2002; 165: 1581-1586.
106. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal function trends. Am J Resp Crit Care Med 2003; 168: 531-537.
107. Steen V. Advancements in Diagnosis of Pulmonary Arterial Hypertension in Scleroderma. Arth Rheum 2005; 52(12): 3698-3700.
108. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: Reproducibility in fibrotic interstitial pneumonia. Am J Resp Crit Care Med 2005; 171: 1150-1157.
109. Flaherty KR, Andrel A, Murray S, et al. Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minutewalk test. Am J Resp Crit Care Med 2006; 174: 803-809.
110. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009; 35: 330-6.
111. Lama VM, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Resp Crit Care Med 2003; 168: 1084-1090.
112. Swigris JJ, Zhou X, Wamboldt FS, et al. Exercise peripheral oxygen saturation (SpO2) accurately reflects arterial oxygen saturation (SaO2) and predicts mortality in systemic sclerosis. Thorax 2009; 64: 626-630.
113. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Resp Crit Care Med 2012; 185: 1044-1048.
114. Komocsi A, Vorobcsuk A, Faludi R, Pinter T, Lenkey Z, Kolto G, Czirjak L. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology 2012; 51(6): 1027-1036.
115. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritisinterstitial lung disease-associated mortality. American journal of respiratory and critical care medicine 2011; 183(3): 372-378.
116. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
117. Noth I, Anstrom KJ, Calvert SB, et al. Idiopathic Pulmonary Fibrosis Clinical Research N: A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 2012; 186(1): 88-95.
118. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE, Jr., Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. The New England journal of medicine 2012; 366(21): 1968-1977.
119. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L, European IPFCG. Hot of the breath: mortality as a primary endpoint in IPF treatment trials: the best is the enemy of the good. Thorax 2012; 67(11): 938-940.
120. Richeldi L, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med 2011; 5(4): 473-81. doi: 10.1586/ers.11.52.
121. Taniguchi H, Kondoh Y, Ebina M, et al. Pirfenidone Clinical Study Group in Japan. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011 Jul 15; 12: 93.
122. de Lauretis A, Veeraraghavan S, Renzoni E. Review series: Aspects of interstitial lung disease: connective tissue diseaseassociated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011; 8(1): 53-82.
123. Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis and rheumatism 2010; 62(7): 2101-2108.
124. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007 Oct 1; 176(7): 636-43.
125. King TE, Jr., Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
126. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969.
127. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97-103.
128. Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29(2): 90-8.